

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LifeTech Scientific Corporation**

**先健科技公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1302)**

### **POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 28 MAY 2019**

The Board announces that the Resolution proposed at the EGM held on 28 May 2019 was not passed.

References are made to the circular of the Company dated 25 April 2019 (the “**Circular**”) and the notice of the EGM dated 25 April 2019 (the “**Notice**”) regarding the proposal for adoption of the 2019 Share Option Scheme and proposed termination of the Existing Scheme. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board announces that the ordinary resolution as set out in the Notice (the “**Resolution**”) was not passed at the EGM held on 28 May 2019. Tricor Investor Services Limited, the Hong Kong branch share registrar of the Company, was appointed as the scrutineer for the vote-taking at the EGM.

The poll results in respect of the Resolution proposed at the EGM were as follows:

<b>Ordinary resolution</b>	<b>Number of votes (Approximate percentage)</b>	
	<b>For</b>	<b>Against</b>
<p>THAT the share option scheme of the Company in the form produced before this meeting and for the purpose of identification marked “A” and signed by the Chairman of the meeting (“2019 Share Option Scheme”) be and is hereby approved and adopted by the Company and subject and conditional upon The Stock Exchange of Hong Kong Limited granting approval of the listing of, and permission to deal in, the shares of the Company which may be issued pursuant to the exercise of any options granted under the 2019 Share Option Scheme, and the directors of the Company be and are hereby authorised to grant options and to allot, issue and deal with the Shares pursuant to the exercise of any option granted thereunder and to take such steps and do such acts and to enter into such transactions, arrangements and agreements as maybe necessary or expedient in order to give full effect to the 2019 Share Option Scheme.</p>	<p>484,677,746 (30.84%)</p>	<p>1,086,686,429 (69.16%)</p>

As less than 50% of the votes cast by way of poll were in favour of the Resolution, the Resolution was not passed. The Existing Scheme, which is due to expire on 21 October 2021, will not be terminated as a result.

As at the date of the EGM, there were a total of 4,328,183,200 Shares in issue entitling the holders of which to attend and vote on the Resolution at the EGM, representing 100% of the total number of issued Shares of the Company. There were no Shares entitling the holders to attend and abstain from voting in favour of the Resolution at the EGM as set out in Rule 13.40 of the Listing Rules and no Shareholders had stated their intention in the Circular to vote against or to abstain from voting on the Resolution at the EGM.

For and on behalf of  
**LifeTech Scientific Corporation**  
**XIE Yuehui**  
*Chairman, Chief Executive Officer  
and Executive Director*

Hong Kong, 28 May 2019

*As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.*